Is de-escalation of adjuvant treatment safe in stage I HER2+ tumors larger than 1 cm?
Paolo Tarantino shared on X:
“Is de-escalation of adjuvant treatment safe also in stage I HER2+ tumors larger than 1 cm?
In ATEMPT, patients receiving T-DM1 had excellent 5-year iDFS (>95%) irrespective of tumor size.”
Read further.
Source: Paolo Tarantino/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer.
With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.